PULMICORT FLEXHALER

With two dosage strengths, PULMICORT FLEXHALER™ allows for adjustable dosing

Dosing
  • Improvement in asthma control following inhaled administration of budesonide can occur within 24 hours of initiation of treatment, although maximum benefit may not be achieved for 1 to 2 weeks, or longer
  • Consider age and disease severity when initiating treatment with PULMICORT FLEXHALER™
  • Patients should be advised that rinsing the mouth with water without swallowing after each dosing may decrease the risk of the development of oral candidiasis
  • Adjust your patient’s daily therapy and step up or step down as needed
    • — Two prescribing strengths: 180-mcg or 90-mcg inhalers
    • — Two age-specific treatment recommendations
    • — For patients with asthma who require oral corticosteroid therapy, PULMICORT FLEXHALER™ may be able to help reduce or eliminate that requirement over time

* Each 180-mcg dose of PULMICORT FLEXHALER™ delivers 160 mcg of budesonide per actuation. Each 90-mcg dose of PULMICORT FLEXHALER™ delivers 80 mcg of budesonide per actuation.

Indications and Important Safety Information for PULMICORT FLEXHALER™

  • PULMICORT FLEXHALER™ is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age or older
  • PULMICORT FLEXHALER™ is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT FLEXHALER™ because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids (see WARNINGS in full Prescribing Information)
  • Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles
  • It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses
  • Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown
  • Rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids
  • Common adverse events reported in clinical trials, regardless of relationship to treatment, include nasopharyngitis, nasal congestion, pharyngitis, allergic rhinitis, and viral upper respiratory tract infection

Please click here for full Prescribing Information for PULMICORT FLEXHALER™.